Produces and markets probiotic-based products. Specializes in drinkable kefir, a cultured dairy product. Now — the numbers.
This is an established company with proven profits.
Average growth of 16% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $5.1M would still be left — though next to the size of the company that is a thin cushion.
The market pays 27.1× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 19% of them.
Analysts' average target sits 30% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 16% a year on average.
There is $5.6M in the vault; even if every debt were paid off, $5.1M would remain.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 19/100.
On our five-subject report card, LWAY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LWAY does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (19/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.